Confident Investing Starts With TipRanks Premium

Get 55% Off
TipRanks
Go Ultimate55% OFF

TG Therapeutics (NKB2) Drug Pipeline

Drug pipeline
Drug NameConditionStageStatusStudy NameTrial Start DateArticle
UblituximabSchizophreniaPhase IIRecruitingStudy to Evaluate the Safety and Efficacy of Ublituximab in Participants With SchizophreniaJun 26, 2026
UblituximabMyasthenia GravisPhase IIRecruitingA Study to Evaluate the Efficacy and Safety of Maintenance Ublituximab Following Induction With Efgartigimod Administration in Participants With Myasthenia Gravis (MG)Jun 10, 2026
Ublituximab, Prefilled PenMultiple SclerosisPhase IIRecruitingA Study to Evaluate Pharmacokinetics (PK) and Safety of Subcutaneous (SC) Ublituximab Administered at Various Injection Sites and Relative Bioavailability Via Autoinjector (AI) Versus Syringe Subcutaneously in Participants With Multiple Sclerosis (MS)Mar 09, 2026
Ublituximab, FingolimodRelapsing Multiple Sclerosisphase2AndPhase3RecruitingStudy to Assess Effects of Ublituximab in Pediatric Participants With Relapsing Forms of Multiple SclerosisOct 22, 2025
UblituximabRelapsing Multiple SclerosisPhase IIIActive Not RecruitingA Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety, Radiological and Clinical Effects of Subcutaneous Ublituximab in Participants With Relapsing Multiple Sclerosis (RMS)Oct 01, 2025
Azercabtagene ZapreleucelB-Cell Mediated Autoimmune DisordersPhase IRecruitingA Study to Assess the Safety and Clinical Activity of Azer-cel in Participants With B-cell Mediated Autoimmune DisordersNov 01, 2024
UblituximabRelapsing Multiple SclerosisPhase IIIRecruitingStudy to Evaluate Safety, Efficacy and Pharmacokinetics (PK) of a Modified Regimen of UblituximabMay 18, 2023
UblituximabRelapsing Multiple Sclerosis (Rms)Phase IIIActive Not RecruitingAn Extension Study of Ublituximab in Participants With Relapsing Multiple SclerosisOct 16, 2019―
Obinutuzumab, Chlorambucil, Ublituximab, Tgr-1202Chronic Lymphocytic LeukemiaPhase IIITerminatedUblituximab + TGR-1202 Compared to Obinutuzumab + Chlorambucil in Participants With Untreated and Previously Treated Chronic Lymphocytic LeukemiaNov 18, 2015―

FAQ

What are the FDA phases for drug approval?
The FDA approval process for new drugs is divided into several phases: a. Preclinical testing b. Phase 1 – Safety and dosage c. Phase 2 – Effectiveness and side effects d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
What is a clinical trial?
A clinical trial is a carefully designed study in which researchers test a drug, treatment, or medical device in people to evaluate its safety, effectiveness, and potential side effects. These trials are essential for determining whether a new treatment should be approved for widespread use.
What drugs does TG Therapeutics (DE:NKB2) have in its pipeline
TG Therapeutics DE:NKB2 is currently developing the following drugs: Ublituximab, Ublituximab, Prefilled Pen, Ublituximab, Fingolimod, Azercabtagene Zapreleucel, Obinutuzumab, Chlorambucil, Ublituximab, Tgr-1202. These drug candidates are in various stages of clinical development as the company works toward FDA approval.